{ }
Symbol NTLA
Name Intellia Therapeutics, Inc.
Currency USD
Sector Health Care
IndustryGroup Pharmaceuticals, Biotechnology & Life Sciences
Industry Biotechnology
Market NASDAQ Global Select
Country United States
State MA
City Cambridge
Zipcode 2139
Website http://www.intelliatx.com
Intellia Therapeutics, Inc. has seen its shares plummet 60.4% in 2024, significantly underperforming the industry and the S&P 500. Despite promising data from its CRISPR-based therapies, including the investigational nexiguran ziclumeran for ATTR amyloidosis, investor disappointment has grown due to recent trial results. The company continues to advance its innovative gene editing pipeline, with ongoing studies showing substantial serum TTR reduction in patients.
CRISPR Therapeutics, a pioneer in gene therapy, faces challenges despite its first FDA-approved CRISPR-based therapy, Casgevy. With shares down 46% from their peak and minimal revenue reported, the company must navigate intense competition and financial losses while aiming for future growth. Investors are advised to proceed with caution until sales momentum is evident.
Cathie Wood, CEO of Ark Invest, stated that her ARK Innovation fund, which has seen significant losses since its peak, should not constitute a large portion of any investment portfolio. She emphasized the fund's volatility and positioned it as a satellite strategy, while highlighting advancements in technologies like genome therapy that could drive future growth. Despite underperformance compared to the S&P 500, Wood remains confident in the fund's unique approach and potential.
Intellia Therapeutics reported mixed Phase 2 results for its CRISPR-based therapy NTLA-2002, aimed at treating hereditary angioedema. The study showed a 75% to 77% reduction in attacks among patients, with some remaining attack-free for months post-treatment. Despite a 20% drop in shares, experts highlight the therapy's potential as a one-time curative option, contrasting it with traditional treatments.
Trending
Subcategory:
Countries:
Companies:
Currencies:
People:

MachinaCore is a highly modular and scalable system that allows users to build custom widgets and tools tailored to their specific financial data needs, while seamlessly integrating with other MachinaLabs products, like Machinary, MachinaAI Modules and MachinaTrader.

Address

Waitlist

We’re granting exclusive early access to the first 500 users from december 20.

© 2024 by Machinary.com - Version: 1.0.0.0. All rights reserved

Layout

Color mode

Theme mode

Layout settings

Seems like the connection with the server has been lost. It can be due to poor or broken network. Please hang on while we're trying to reconnect...
Oh snap! Failed to reconnect with the server. This is typically caused by a longer network outage, or if the server has been taken down. You can try to reconnect, but if that does not work, you need to reload the page.
Oh man! The server rejected the attempt to reconnect. The only option now is to reload the page, but be prepared that it won't work, since this is typically caused by a failure on the server.